ATE388165T1 - Menschliches cnp-gen und vorläuferprotein - Google Patents

Menschliches cnp-gen und vorläuferprotein

Info

Publication number
ATE388165T1
ATE388165T1 AT96114549T AT96114549T ATE388165T1 AT E388165 T1 ATE388165 T1 AT E388165T1 AT 96114549 T AT96114549 T AT 96114549T AT 96114549 T AT96114549 T AT 96114549T AT E388165 T1 ATE388165 T1 AT E388165T1
Authority
AT
Austria
Prior art keywords
precussion
protein
human cnp
human
cnp gene
Prior art date
Application number
AT96114549T
Other languages
English (en)
Inventor
Shoji Tanaka
Kayoko Kawashima
Yasunori Tawaragi
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Asubio Pharma Co Ltd
Hisayuki Matsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asubio Pharma Co Ltd, Hisayuki Matsuo filed Critical Asubio Pharma Co Ltd
Application granted granted Critical
Publication of ATE388165T1 publication Critical patent/ATE388165T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96114549T 1990-09-27 1991-09-27 Menschliches cnp-gen und vorläuferprotein ATE388165T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP02259698A JP3026354B2 (ja) 1990-09-27 1990-09-27 ヒトｃｎｐ遺伝子及び前駆体蛋白

Publications (1)

Publication Number Publication Date
ATE388165T1 true ATE388165T1 (de) 2008-03-15

Family

ID=17337688

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96114549T ATE388165T1 (de) 1990-09-27 1991-09-27 Menschliches cnp-gen und vorläuferprotein
AT91116557T ATE162532T1 (de) 1990-09-27 1991-09-27 Merschliches cnp-gen und vorläufer protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT91116557T ATE162532T1 (de) 1990-09-27 1991-09-27 Merschliches cnp-gen und vorläufer protein

Country Status (8)

Country Link
US (1) US6034231A (de)
EP (2) EP0769554B1 (de)
JP (1) JP3026354B2 (de)
AT (2) ATE388165T1 (de)
DE (2) DE69133593T2 (de)
DK (1) DK0477971T3 (de)
ES (2) ES2302333T3 (de)
GR (1) GR3026554T3 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
AU2003297583B2 (en) 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
ES2465141T3 (es) * 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
EP3446711A1 (de) 2004-03-31 2019-02-27 Kazuwa Nakao Zusammensetzung zur erhöhung der körpergrösse
PL3404102T3 (pl) 2004-04-21 2021-12-13 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
US20080207505A1 (en) * 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
US20070184466A1 (en) * 2005-11-18 2007-08-09 The Brigham And Women's Hospital, Inc. Detection, generation and uses of atherosclerosis-protective endothelium
AU2008326327A1 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
JP5524049B2 (ja) * 2008-05-23 2014-06-18 第一三共株式会社 目的ペプチドの血漿中半減期延長作用を有するペプチド
MX2011012277A (es) * 2009-05-20 2011-12-12 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c.
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
KR20180030414A (ko) 2015-07-30 2018-03-22 바이오마린 파머수티컬 인크. 골 이형성증 치료를 위한 c―형 나트륨이뇨 펩타이드 변이체의 용도
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3436052A4 (de) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. Behandlung von muskelschwäche mit alkalischen phosphatasen
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
US11224637B2 (en) 2017-03-31 2022-01-18 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
MX2022003184A (es) 2019-09-16 2022-06-23 Biomarin Pharm Inc Variantes del cnp y sus conjugados.
WO2023283657A1 (en) 2021-07-09 2023-01-12 Biomarin Pharmaceutical Inc. C-type natriuretic peptide variants to treat skeletal dysplasia in children
WO2023108005A1 (en) 2021-12-07 2023-06-15 Biomarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
DE69128754T2 (de) 1998-06-04
JP3026354B2 (ja) 2000-03-27
EP0769554A2 (de) 1997-04-23
JPH04139199A (ja) 1992-05-13
EP0477971A3 (en) 1992-09-09
US6034231A (en) 2000-03-07
DK0477971T3 (da) 1998-09-21
ES2302333T3 (es) 2008-07-01
ES2113865T3 (es) 1998-05-16
DE69133593D1 (de) 2008-04-17
EP0477971B1 (de) 1998-01-21
ATE162532T1 (de) 1998-02-15
DE69133593T2 (de) 2009-04-02
DE69128754D1 (de) 1998-02-26
EP0477971A2 (de) 1992-04-01
EP0769554B1 (de) 2008-03-05
GR3026554T3 (en) 1998-07-31
EP0769554A3 (de) 1997-05-28

Similar Documents

Publication Publication Date Title
ATE388165T1 (de) Menschliches cnp-gen und vorläuferprotein
IL131016A0 (en) Selection of proteins using rna-protein fusions
DE69131699D1 (de) Verändertes menschliches iL-6
DE3672924D1 (de) Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen.
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
ES2076999T3 (es) Peptidos anticoagulantes radiomarcados.
NO971875D0 (no) Cathepsin 02 protease
ES2146193T1 (es) Proteinas del virus del arrugado de las hojas de la vid (tipo 2) y sus usos.
HU906270D0 (en) Anticoagulant peptides
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
IL92551A0 (en) Anticoagulant peptides
EP0723016A3 (de) Leukocyten-aktivierender Faktor
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
ES2059801T3 (es) Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas.
ATE75255T1 (de) Peptid und dafuer kodierendes gen.
DE3888078T2 (de) Veränderungsverfahren für Peptide und Proteine.
IE882662L (en) Dna sequences, recombinant dna molecules for producing¹soluble t4 proteins
ATA166890A (de) Rekombinantes dna-molekül für allergene des erlenpollens, damit hergestellte proteine bzw. polypeptide, sowie deren anwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties